Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte.

Détails

ID Serval
serval:BIB_29086DF23A7F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Infectious adverse events in children with Juvenile Idiopathic Arthritis treated with Biological Agents in a real-life setting: Data from the JIRcohorte.
Périodique
Joint, bone, spine
Auteur(s)
Dumaine C., Bekkar S., Belot A., Cabrera N., Malik S., von Scheven A., Carbasse A., Woerner A., Wouters C., Bouayed K., Pillet P., Schroeder S., Hofer M., Hentgen V.
ISSN
1778-7254 (Electronic)
ISSN-L
1297-319X
Statut éditorial
Publié
Date de publication
01/2020
Peer-reviewed
Oui
Volume
87
Numéro
1
Pages
49-55
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
The main objective of our study is to assess the infectious adverse events occurring in juvenile idiopathic arthritis (JIA) children treated with biological agents.
Patients were selected from the retrospective module of the JIRcohorte, data concerning the period between January 2001 and August 2015. All infectious adverse events (IAE) were retrieved. For every infectious side effect, the date, the severity, the need for a hospitalization, the type of pathogen and the affected organ were noted. Incidence rates were expressed in number of events per 100 person-years (100p-y), and OR were calculated.
Six hundred seventy-seven patients with JIA were included in the study. A total of 3075.4 person-years of exposure were analyzed. One hundred eighty-four infectious events were described (6.0 events/100 p-y): 15.5/100 p-y with tocilizumab (TCZ), 9.6/100 p-y with Canakinumab (CAN), 7.4/100 p-y with abatacept (ABA), 6.9/100 p-y with Golimumab (GOL), 6.7/100 p-y with Anakinra (ANA), 6.3/100 p-y with Infliximab, 4.8/100 p-y with Etanercept, and 3.7/100 p-y with Adalimumab. Risk of developing an infection was significantly higher with IL-6 antagonists or IL-1 antagonists than with TNF-inhibitor. Forty point eight percent of the infectious adverse events (IAE) affected the upper respiratory tract or the Ear, nose and throat (ENT) system. Twelve infectious adverse events were described as severe or very severe (0.4/100p-y). No case of tuberculosis or death was reported.
Infectious complications with biologics occurring in children treated for JIA are rare, and in most of the cases have a mild or moderate severity, affecting mainly the upper respiratory tract or the ENT.
Mots-clé
Juvenile Idiopathic Arthritis, biologics, infections
Pubmed
Web of science
Création de la notice
18/08/2019 16:19
Dernière modification de la notice
15/07/2021 6:36
Données d'usage